Pharmaceutical Technology E-Alert:
Having trouble viewing this e-mail? Click here.
You are subscribed to %%list.name%% as %%emailaddr%%.
Click here to unsubscribe or edit your member profile.
  Pharmaceutical Technology Europe E-Alert
 
23 July 2010
IN THIS ISSUE
Generic firms sued
FDA joins Tox21
Pfizer halts trial
Merck acquires Millipore
 
Pfizer and Nycomed sue generic firms
Teva and Sun Pharmaceuticals’ motion to overturn a verdict issued against them in April 2010 for patent infringement has been denied by a US court, leaving the companies at the mercy of pharma giants Pfizer and Nycomed, who have said they will “vigorously” pursue damage claims. More...
 
FDA joins chemical screening collaboration
The FDA has joined the Tox21 collaboration, which aims to develop ways to more effectively predict how chemicals will affect the body and environment. More...
 
Pfizer halts trial over safety concerns
Pfizer has been asked by the FDA to suspend chronic pain studies involving tanezumab because of safety concerns. The investigational compound had been touted by some as a potential blockbuster. More...
 
Merck completes Millipore acquisition
Merck KGaA has completed its acquisition of Millipore for an aggregate purchase price of roughly $6.7 billion. More...
 
SOCMA voices concern over chemical-site security bill
The Society of Chemical Manufacturers and Affiliates (SOCMA) has expressed “strong concern” over legislation introduced in the US Senate earlier this month regarding chemical-site security. More...
 
Microneedles boost vaccine efficacy
Researchers claim that a dissolving microneedle patch may be able to offer improved vaccination against influenza compared with traditional needles, and also allow people without medical training to easily and safely administer the vaccine. More...
 
Join our community on LinkedIn
Want to discuss any of this week’s news stories or any other hot topics in the industry? Then why not join our group on LinkedIn? More...

Latest blog posts
When innovation stops short
AstraZeneca versus the European Commission
A timeline of J&J/McNeil’s recent recall troubles
More blog posts

PTE Digital
Data Matrix barcodes: points to consider
Overt versus covert technologies
Anticounterfeiting product showcase
Read the full issue

Upcoming events
Pharmaceutical Tablet Technology (9–11 August | USA)
2010 PDA/FDA Joint Regulatory Conference (13–16 September | USA)
Extractables & Leachables for Pharmaceutical Products 2010 (14–15 September | UK)
More events

Product Profile
Veltek's new sterile clean room wipes

Veltek debuts new sterile clean room wipes, including the industry's first sodium hypochlorite and hydrogen peroxide clean room wipes.

Read more...


Event Profile
Extractables & Leachables for Pharmaceutical Products 2010

14-15 September 2010
Holiday Inn London Kings Cross Bloomsbury, London


Impurities originating from any part of the manufacturing or storage of drug products can potentially result in expensive product recalls and damage to a company’s reputation, not to mention the serious threat posed to patient safety.

Read more...



Podcast
Vetter
The North American market is critical to Vetter’s strategic global growth as nearly half of its client base is already located here. In order to maximize on this opportunity, Vetter has decided to create a facility, its first outside of Germany, at the Illinois Science + Technology Park in suburban Chicago.

Expansion of Vetter Development Service (VDS)


Survey
Has your company initiated a program to make its processes more green?
Yes   62%
No   38%

This week we would like to know...

What is your opinion of the rising trend in the pharma industry to outsource functions to emerging countries?
Click here to vote

Contact Us
Click here to contact editorial.

Click here to contact sales.

 
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone
numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact
information available to third parties for marketing purposes, please contact us by emailing [email protected] or by mail
at Advanstar Communications Inc., Advanstar House, Park West, Sealand Road, Chester, CH1 4RN United Kingdom